Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002537 · ClinicalTrials.gov registry record · Phase 1
Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer
A Phase 1 study of Lung Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00002537: Completed Phase 1 study of Lung Cancer, sponsored by National Cancer Institute (NCI).
NCT00002537 is a Phase 1 study of Lung Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 20 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002537, a Phase 1 study of Lung Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy may kill more tumor cells.
Conditions Studied
Interventions
- RADIATION radiation therapy
- DRUG topotecan hydrochloride
Study Locations (1)
New York
- NYU School of Medicine's Kaplan Comprehensive Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1993-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002537
The ClinicalTrials.gov registry entry for NCT00002537 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which radiation therapy is the first listed.
NCT00002537 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00002537 about?
NCT00002537 is a clinical study titled "Radiation Therapy Plus Topotecan in Treating Patients With Non-small Cell Lung Cancer". Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy may kill mo...
What is the current status of trial NCT00002537?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1993-09.
What conditions does trial NCT00002537 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT00002537?
The interventions under investigation include: radiation therapy (RADIATION), topotecan hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00002537?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002537 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.